In summary, this study underscores the efficacy and safety of SNS for breast cancer patients with MMD, and highlights the potential pathway of Lactobacillus-Indole-CD8+ T cell in mediating the pharmacological activities of SNS. This evidence concerns the gene CD8A and multiminicore myopathy.